300676 BGI Genomics
- 41.13
- -0.08-0.19%
BGI Genomics News
Express News | BGI: In the future, it will promote the integration and innovation of big models of artificial intelligence and multi-omics data
Express News | BGI: Net profit of 92.9 million yuan in 2023, a year-on-year decrease of 88.43%. It plans to pay 1 yuan for 10.
Building a Better Future: NJ Roofing Companies Partner With BGI to Empower Communities
CARLSTADT, N.J., April 5, 2024 /PRNewswire/ -- In a testament to the power of community and shared purpose, a collective of New Jersey roofing companies has announced a unique partnership with Busine
Next Generation Sequencing Market Size Is Set to Grow by USD 3409.76 Million From 2023-2027, 10X Genomics Inc., Azenta Inc. & BGI Genomics Co. Ltd., and More to Emerge as Some of the Key Vendors, Technavio
The global next generation sequencing market size is estimated to grow by USD 3409.76 million from 2023 to 2027, according to Technavio. The market...
Uniting for Women's Wellness on IWD - From China to Uzbekistan
- Interviewing Wang Leilei, the first blind model in China, and Viktoriya Tsay, head of Prenatal and Neonatal Medicine Department at Genscreen, BGI Genomics JV laboratory in Uzbekistan. HONG KONG, Mar
Pharmacovigilance has collectively plummeted! Yao Ming and Kangde quickly responded
Up to now, there has been a sharp drop across the board for medicinal products. A-share Pharmaceutical Kangde fell to a standstill, Hong Kong stock Yao Ming Kangde fell nearly 19%, and Pharmaceutical Biotech fell more than 21%.
Express News | The US Biosafety Act moved forward and was criticized as a “narrow protectionist act,” and medicine clearly responded
The US Senate version of the Biosafety Act was passed at a hearing last night. What is the situation, and how should the Pharmacovigilance Department respond?
The industry believes that the bill may be fiercely discussed and repeatedly revised in the Senate and House of Representatives, and that relevant companies should “think from the bottom line.”
Express News | US Senate version of “Biosafety Act” passed hearing House bill hearing will be held soon
Pharmacovigilance is raging! The CRO sector has exploded. What do you think of the future market? Focus on 3 key events
CITIC Securities believes that short-term fluctuations in overseas policies do not affect the long-term fundamental logic of Chinese pharmaceutical outsourcing companies.
Transferring overseas is a huge benefit! The CXO sector surged, and Yao Ming Kangde and Pharmaceutical Biotech rose more than 11%
The medicine sector is quite annoying.
Express News | BGI Performance Report: Net profit due to mother fell 88.64% year on year in 2023
Huada Gene (300676.SZ): Chromosomal aneuploidy and fragment deletion testing products obtained medical device registration certificates
Huada Gene (300676.SZ) issued an announcement. Huada Biotechnology (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company...
BGI (300676): Leading gene sequencing service in cost reduction and diversification
Key investment points Huada Gene is an established domestic leading genetic sequencing service enterprise. Upstream breaks through overseas monopoly restrictions to achieve cost reduction and downstream expansion of application scenarios and overseas channels. In 2023-2025, as overseas expansion accelerates, regular business revenue will increase
Next-Generation Sequencing Emerging Clinical Applications and Global Markets, With Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.Since NGS platforms can sequence
Express News | The number of members who co-sponsored the US Senate version of the Life Safety Act was reduced from 6 to 0
Changes in Hong Kong stocks: Yao Ming has collectively boosted, and supporters of the US Senate version of the draft have dropped to zero
Gelonghui, Feb. 7 | The Hong Kong stock market collectively boosted. Pharmacom Kangde and Yao Ming Biotech rose 9%, and Pharmacom Joint rose more than 11%. According to Reuters, the number of co-sponsors of the Senate version of the US biosafety draft, which previously proposed sanctions against it, was reduced from 6 to 0. The bill was submitted to the Senate on December 20 last year, but it was not advanced in the Senate last week. A similar proposal was submitted to the House of Representatives on January 25, but there are still 4 supporters. The draft seeks to restrict the US federal government's procurement of biotechnology equipment and services from Kangde and BGI. In the US, lawmakers who initiated the bill can seek to co-sponsor
Express News | Foreign media: US Senate postpones review of the biotechnology-related Chinese enterprise bill
Huada Gene (300676): Regular business is growing steadily, and overseas localization platforms are gradually gaining strength
Event: The company released the 2023 performance forecast. The company's 2023 revenue is estimated to be about 4.2 billion yuan to 4.5 billion yuan (-36.14% ~ -40.39%), and net profit to mother of 80 million yuan~1
Express News | BGI: Net profit is expected to drop 86.30%-90.04% year-on-year in 2023
Analysis
Price Target
No Data
